Lenvatinib is an oral tyrosine kinase inhibitor that targets multiple receptors, inhibiting VEGFR and FGFR signaling pathways, which are crucial for angiogenesis in tumors. It has shown significant efficacy in treating radioiodine-refractory thyroid cancer and advanced renal cell carcinoma in combination with everolimus, with ongoing evaluations in other cancer types. This study aimed to clarify the mechanistic action of lenvatinib's therapeutic effects using both in vitro and in vivo models.

1. Global Journal of Cancer
Therapy
Peertechz Journals

2. Research Article
Lenvatinib Suppresses Angiogenesis through
the Inhibition of both the VEGFR and FGFR
Signaling Pathways
 Kenji Ichikawa, Saori Watanabe Miyano, Yusuke Adachi, Masahiro
Matsuki, Kiyoshi Okamoto and Junji Matsui*
 *Corresponding author: Junji Matsui, Ph, D, Biology Research, Oncology
Tsukuba Research Department, Discovery, Medicine Creation, Oncology
Business Group, Eisai Co., Ltd., 5-1-3 Tokodai, Tsukuba-shi, Ibaraki 300-
2635, Japan, Tel: +81-29-847-5808, Fax: +81-29-847-5367;
 Dates: Received: 17 June, 2016; Accepted: 01 July, 2016; Published: 02
July, 2016.
 Citation: Ichikawa K, Miyano SW, Adachi Y, Matsuki M, Okamoto K, et al.
(2016) Lenvatinib Suppresses Angiogenesis through the Inhibition of both
the VEGFR and FGFR Signaling Pathways. Glob J Cancer Ther 2(1): 019-
025.

3. Abstract
 Lenvatinib mesilate (lenvatinib) is an oral multiple-receptor tyrosine
kinase inhibitor that selectively inhibits the kinase activities of
Vascular Endothelial Growth Factor Receptor (VEGFR) 1-3, Fibroblast
Growth Factor Receptor (FGFR) 1-4, Platelet-Derived Growth Factor
Receptor (PDGFR) α, KIT, and RET. The VEGFR and FGFR signaling
pathways are the master regulators of normal and tumor angiogenesis.
Lenvatinib showed significant activity in patients with radioiodine-
refractory thyroid cancer in a Phase III study and is used in the United
States, the European Union, and Japan. Moreover, based on Phase II
study, lenvatinib has been approved in the United States for the
treatment of patients with advanced renal cell carcinoma in
combination with everolimus. In addition, the efficacy of lenvatinib is
being evaluated in other cancers, including hepatocellular carcinoma
and endometrial cancer. The purpose of this study was to elucidate the
mechanism underlying the clinical activities of lenvatinib by using in
vitro and in vivo angiogenesis models.

4. Thank you
For more information Read Online Article…
http://www.peertechz.com/Cancer-Therapy/GJCT-1-109.pdf
For
Full
Article
PDF